Soligenix (SNGX) Q2 2025 earnings summary

Executive summary

• Net loss increased to $2.7M for Q2 2025 and $5.7M for H1 2025, driven by higher R&D expenses for clinical trials and lower other income compared to the prior year.

• No revenue recognized in Q2 or H1 2025, compared to $2.3K and $119K in the same periods last year, due to timing of government grant support.

• Ongoing development of key pipeline assets, including HyBryte™ (CTCL), SGX302 (psoriasis), SGX942 (oral mucositis), and SGX945 (Behçet's Disease), with multiple clinical milestones achieved or underway.

• Management highlights substantial doubt about the ability to continue as a going concern beyond Q1 2026 without additional capital.

Financial highlights

• Cash and cash equivalents were $5.1M as of June 30, 2025, down from $7.8M at year-end 2024.

• Working capital decreased to $1.7M from $4.0M at December 31, 2024.

• Research and development expenses rose to $1.68M for Q2 2025 (up $1.18M YoY) and $3.62M for H1 2025 (up $2.02M YoY), mainly due to clinical trial and manufacturing costs.

• General and administrative expenses decreased to $1.09M for Q2 2025 (down $157K YoY) and $2.17M for H1 2025 (down $94K YoY), reflecting lower professional fees.

• Interest income, net, increased to $69.8K for Q2 2025 and $145.9K for H1 2025, due to reduced interest expense after debt repayment.

Outlook and guidance

• Management expects continued losses and negative cash flow, with sufficient resources to support operations only through Q1 2026.

• Plans to secure additional capital via equity offerings, strategic transactions, and government grants; ATM facility fully utilized as of July 1, 2025.

• Ongoing enrollment in the confirmatory Phase 3 FLASH2 trial for HyBryte™ in CTCL, with top-line results anticipated in H2 2026.

• Continued expansion of pipeline programs, including Phase 2a trials for SGX302 and SGX945, and pursuit of partnerships for SGX942.